会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Pharmaceutically active compounds
    • 药物活性化合物
    • US06492406B1
    • 2002-12-10
    • US09646972
    • 2000-09-25
    • Kostas KarabelasMatti LepistöPeter Sjö
    • Kostas KarabelasMatti LepistöPeter Sjö
    • C07D40314
    • C07D403/04A61K31/4196C07D403/14
    • The present invention relates to novel compounds which are protein kinase C inhibitors, methods for their preparation, intermediates therefor and pharmaceutical compositions comprising them. More particularly, the present invention relates to compounds of formula (I): wherein: one of Ar1 and Ar2 is optionally substituted bicyclic heteroaryl or optionally substituted tricyclic heteroaryl and the other is optionally substituted heteroaryl or optionally substituted aryl; X is O or S; and R is H, OH, NH2 or C1-6 alkyl (itself optionally substituted by amino or hydroxy); or a salt or solvate thereof, or a solvate of a salt thereof; and the use of such compounds in medical therapies.
    • 本发明涉及蛋白激酶C抑制剂的新化合物,其制备方法,其中间体和包含它们的药物组合物。 更具体地说,本发明涉及式(I)的化合物:其中:Ar 1和Ar 2之一是任选取代的双环杂芳基或任选取代的三环杂芳基,另一个是任选取代的杂芳基或任选取代的芳基; X是O或S; 且R为H,OH,NH 2或C 1-6烷基(其本身任选被氨基或羟基取代); 或其盐或溶剂合物,或其盐的溶剂合物; 以及这些化合物在医学疗法中的应用。
    • 5. 发明授权
    • Pharmaceutically active compounds
    • 药物活性化合物
    • US6153641A
    • 2000-11-28
    • US981003
    • 1997-12-18
    • H.ang.kan BergstrandThomas HogbergKostas KarabelasAnders Tunek
    • H.ang.kan BergstrandThomas HogbergKostas KarabelasAnders Tunek
    • A61P37/00C07D401/14C07D403/14C07D409/14C07D487/04A61K31/404C07D403/04
    • C07D401/14C07D403/14C07D409/14C07D487/04
    • The present invention provides novel compounds of the formula (I):R.sub.20 --(CH.sub.2).sub.n --R (I)wherein:T.sub.20 is a bisindolylmaleimide moiety linked to the --(CH.sub.2).sub.n -group through an indolyl nitrogen,n is 0 or 1,R is a 5 or 6 membered aromatic carbocyclic or heterocyclic ring, the heterocyclic ring containing N or S,R is substituted by R.sub.1 and up to four of R.sub.2, R.sub.3, R.sub.4 and R.sub.5,wherein;R.sub.1 is aminomethyl, (N--(C.sub.1-4 -alkyl)amino)methyl, (N,N-di(C.sub.1-4 -alkyl)amino)methyl or pyridiniummethyl, andR.sub.2, R.sub.3, and R.sub.4 and R.sub.5 (if present), which may be the same or different, are each hydrogen, hydroxy, C.sub.1-4 -alkoxy, C.sub.1-4 -alkoxy) or halogen,or R.sub.2 when in a position contiguous to the bond connecting R to the --(CH.sub.2).sub.n -- group and n is 1 may, together with the 2-carbon atom on the indole to which the --(CH.sub.2) group is attached, form a ring,and pharmaceutically acceptable salts thereof; and the use of such compounds in medical therapy.
    • PCT No.PCT / SE97 / 01504 Sec。 371 1997年12月18日第 102(e)1997年12月18日PCT PCT 1997年9月8日PCT公布。 公开号WO98 / 11102 日期:1998年3月19日本发明提供式(I)的新化合物:R 20 - (CH 2)n R(I)其中:T 20是通过吲哚基氮连接至 - (CH 2)n - 基的双吲哚基马来酰亚胺部分,n 是0或1,R是5或6元芳族碳环或杂环,含有N或S的杂环,R被R 1和多至四个R 2,R 3,R 4和R 5取代,其中: R1是氨基甲基,(N-(C1-4 - 烷基)氨基)甲基,(N,N-二(C1-4 - 烷基)氨基)甲基或吡啶鎓甲基,R2,R3和R4以及R5(如果存在) ,其可以相同或不同,分别为氢,羟基,C 1-4 - 烷氧基,C 1-4 - 烷氧基)或卤素,或者当R 2连接至 - (CH 2)n - 基团和n为1可以与 - (CH 2)基团连接的吲哚上的2-碳原子一起形成环,及其药学上可接受的盐; 以及这些化合物在药物治疗中的应用。
    • 7. 发明授权
    • Kinase inhibitors
    • 激酶抑制剂
    • US06492409B1
    • 2002-12-10
    • US09743618
    • 2001-01-12
    • Kostas KarabelasMatti LepistöPeter Sjö
    • Kostas KarabelasMatti LepistöPeter Sjö
    • A61K314178
    • C07D403/04C07D403/14C07D409/14C07D471/04
    • The present invention relates to compounds of formula (I) wherein: Ar1 or Ar2 is an optionally substituted indole, and the other group is an optionally substituted aromatic or heteroaromatic group, suitably an optionally substituted bicyclic heteroaromatic group, preferably an optionally substituted indole, X is O or S, R is H, OH, NH2, C1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, and R1 is H, C1-6alkyl, fluoro substituted C1-6alkyl, phenyl, benzyl, carboC1-6alkoxy, carbobensyloxy, carbohydroxy, carbamoyl, or methyl(N-C1-6alkylcarbamoyl) and salts and solvates thereof and solvates of such salts, and the use of such compounds in medical therapies.
    • 本发明涉及式(I)化合物,其中:Ar 1或Ar 2是任选取代的吲哚,另一个基团是任选取代的芳族或杂芳族基团,合适地是任选取代的双环杂芳族基团,优选任选取代的吲哚,X 是O或S,R是H,OH,NH 2,C 1-6烷基,羟基C 1-6烷基,氨基C 1-6烷基,R 1是H,C 1-6烷基,氟取代的C 1-6烷基,苯基,苄基,碳C 1-6烷氧基,碳苯氧基, ,氨基甲酰基或甲基(N-C 1-6烷基氨基甲酰基)及其盐和溶剂合物以及这些盐的溶剂合物,以及这些化合物在医学疗法中的用途。
    • 8. 发明授权
    • Bis-aryl or heteroaryl indoles
    • 双芳基或杂芳基吲哚
    • US06337342B1
    • 2002-01-08
    • US09230710
    • 1999-01-29
    • Kostas KarabelasMatti LepistoPeter Sjö
    • Kostas KarabelasMatti LepistoPeter Sjö
    • A61K314152
    • C07D403/04C07D403/14C07D409/14C07D471/04
    • The present invention relates to compounds of formula (I): wherein: Ar is an optionally substituted aromatic or heteroaromatic group, R1 is H, C1-6alkyl, CF3, phenyl, benzyl, carboC1-6alkoxy, carbamoyl, or methyl(N—C1-6alkylcarbamoyl) R2 is H, C1-6alkyl, aminoC1-6alkyl, hydroxyC1-6alkyl, (mono- or di- C1-6alkyl)aminoC1-6alkyl, (aminoC1-3alkylphenyl)C1-3alkyl, amidinothio C1-6alkyl, R3 is H or C1-6alkoxy, R4 is H or together with R2, forms an annulated ring which may be substituted by hydroxyC1-3alkyl or amidinothio C1-3alkyl, or aminoC1-3alkyl; and pharmaceutically acceptable salts thereof; and the use of such compounds in medical therapies.
    • 本发明涉及式(I)的化合物:其中:Ar是任选取代的芳族或杂芳族基团,R 1是H,C 1-6烷基,CF 3,苯基,苄基,C 1 -C 6烷氧基,氨基甲酰基或甲基(N-C 1 (烷基氨基甲酰基)R 2是H,C 1-6烷基,氨基C 1-6烷基,羟基C 1-6烷基,(单 - 或二 - C 1-6烷基)氨基C 1-6烷基,(氨基C 1-3烷基苯基)C 1-3烷基,脒基硫代C 1-6烷基,R 3是H 或C 1-6烷氧基,R 4是H或与R 2一起形成可以被羟基C 1-3烷基或脒基C 1-3烷基或氨基C 1-3烷基取代的环状环;及其药学上可接受的盐;以及这些化合物在医学上的用途 疗法。